flow trial semaglutide renal outcomes 2024 kidney results Media Centre Media Centre | EASD

A:We have strictly quality control system in our production process

10.1016/j.sajb.2007.03.006 116 NiehlA.LacommeC.ErbanA.KopkaJ.KrmerU.FisahnJ

Because interaction of GLP-1 with receptors in the intestine is sufficient to activate all major responses required to impact both diabetes and obesity, it is anticipated that the administration of GLP-1 receptor agonist (GLP-1 RA) in such a way that they pass across intestinal tissue, should be an ideal method for delivering these peptides

The frequency of these injections can vary, from weekly to monthly, based on the individuals needs and the doctors recommendations

Psychiatry 57 , 169173 (1994)